Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Mitacs brings innovation to more people in more places across Canada and around the world.
Learn MoreWe work closely with businesses, researchers, and governments to create new pathways to innovation.
Learn MoreNo matter the size of your budget or scope of your research, Mitacs can help you turn ideas into impact.
Learn MoreThe Mitacs Entrepreneur Awards and the Mitacs Awards celebrate inspiring entrepreneurs and innovators who are galvanizing cutting-edge research across Canada.
Learn MoreDiscover the people, the ideas, the projects, and the partnerships that are making news, and creating meaningful impact across the Canadian innovation ecosystem.
Learn MoreMultiple sclerosis (MS) is a chronic degenerative disease in which central nervous system demyelination and white matter inflammation leads to axonal injury and neurological deficit. Canada has one of the highest rates of MS incidence in the world; studying the pathogenesis of MS is of the utmost importance. MS pathology results from myelin-directed autoimmune attack by T cells of the immune system, and the immune components of the pathology can be recapitulated in mice using the experimental autoimmune encephalomyelitis (EAE) model.
We aim to assess the contribution of specific genes (and by extension, specific molecular pathways) to T-cell-driven EAE pathogenesis, exploiting transgenic mouse strains that possess myelin antigen-specific CD4+ and CD8+ T cells. When transferred to naive recipient animals, these cells induce symptoms of EAE characterized by paralysis of the extremities. Transgenic myelin antigen-specific T cells can thus be isolated and manipulated in vitro, before being transferred to naive recipients, to assess the effects of pharmacological or genetic treatments on their pathogenic capacity.
This project will entail the overexpression or knockdown of specific genes in these cells using retrovirally-mediated gene delivery followed by the transfer of the cellsto recipient mice to assess their ability to induce EAE. Our ultimate aim is to identify novel therapeutic targets for the immunomodulatory treatment of MS.
Manu Rangachari
AZUCENA GONZALEZ GOMEZ
Medicine
Globalink
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.